Sonnen Shares Renewed Stance on TRT | UFC News
It seems like you can’t go anywhere in the world of MMA without hearing the word testosterone, and while there is a plethora of MMA fighters who use testosterone, it still rides a fine line between fair and unfair.
One of the most notable MMA fighters who has been put in the testosterone replacement therapy, or TRT, spotlights is number one light-heavyweight contender, Chael Sonnen.
Chael tested positive for elevated levels of testosterone following a UFC 117 loss to Anderson Silva for the middleweight title, for which, he was suspended. Sonnen returned to the sport with a license that granted him exemption for the use of TRT.
As for UFC president Dana White, he stated at the UFC on FUEL TV 7 card that he will be putting together new testing regimens to ensure that fighters aren’t abusing the privilege of using TRT.
In response, Chael Sonnen opened up on UFC Tonight about his renewed stance:
“First off, I admire Dana on many levels. But for me, this is his crowning moment, both as a leader, but also with his integrity. You are never going to find a chief executive of any corporation, be it sport, business or otherwise that shines a light on his own organization and says, ‘We have a problem.’ Guys, we’re not talking about testosterone use, we’re talking about testosterone abuse.”
Sonnen also claims that since Dana White’s announcement of new testing, that he has already been tested:
“The testing has already started. I can tell you firsthand, I have already been tested since this announcement,”
Sonnen will next face rival coach Jon Jones on April 27th in Newark, New Jersey at UFC 159. The bout will be for the light-heavyweight championship and will mark Jones 5th attempted title defense with a win putting him above Chuck Liddell’s record for title defenses in the 205-pound division.
Thanks to MMAWeekly.com for the lead.
For the latest MMA news visit BJPENN.com
2 Responses to “Sonnen Shares Renewed Stance on TRT | UFC News”
Leave a Reply
You must be logged in to post a comment.